Robert J Mairs
Overview
Explore the profile of Robert J Mairs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nile D, Rae C, Walker D, Waddington J, Vincent I, Burgess K, et al.
Cancer Metab
. 2021 May;
9(1):24.
PMID: 34011385
Background: Neuroblastoma accounts for 7% of paediatric malignancies but is responsible for 15% of all childhood cancer deaths. Despite rigorous treatment involving chemotherapy, surgery, radiotherapy and immunotherapy, the 5-year overall...
2.
Rae C, Mairs R
Oncotarget
. 2019 Feb;
10(7):749-759.
PMID: 30774777
Although radiotherapy is often used to treat localized disease and for palliative care in prostate cancer patients, novel methods are required to improve the sensitivity of aggressive disease to ionizing...
3.
Rae C, Babich J, Mairs R
Chirality
. 2016 Dec;
29(1):10-13.
PMID: 27901292
The elevated activity of fatty acid synthase has been reported in a number of cancer types. Inhibition of this enzyme has been demonstrated to induce cancer cell death and reduce...
4.
Rae C, Mairs R
Int J Radiat Biol
. 2016 Sep;
93(2):194-203.
PMID: 27600766
Purpose: Despite recent advances in the treatment of metastatic prostate cancer, survival rates are low and treatment options are limited to chemotherapy and hormonal therapy. Although ionizing radiation is used...
5.
Nile D, Rae C, Hyndman I, Gaze M, Mairs R
BMC Cancer
. 2016 Aug;
16:621.
PMID: 27515310
Background: The radiopharmaceutical (131)I-meta-iodobenzylguanidine ((131)I-MIBG) is an effective treatment for neuroblastoma. However, maximal therapeutic benefit from (131)I-MIBG is likely to be obtained by its combination with chemotherapy. We previously reported...
6.
Paillas S, Ladjohounlou R, Lozza C, Pichard A, Boudousq V, Jarlier M, et al.
Antioxid Redox Signal
. 2016 May;
25(8):467-84.
PMID: 27224059
Aims: We investigated whether radiation-induced nontargeted effects are involved in the cytotoxic effects of anticell surface monoclonal antibodies labeled with Auger electron emitters, such as iodine 125 (monoclonal antibodies labeled...
7.
Tesson M, Rae C, Nixon C, Babich J, Mairs R
J Pharm Pharmacol
. 2016 May;
68(7):912-21.
PMID: 27139157
Objectives: Despite recent advances in the treatment of metastatic prostate cancer, survival rates are low and treatment options are limited to chemotherapy and hormonal therapy. (131) I-MIP-1095 is a recently...
8.
Rae C, Haberkorn U, Babich J, Mairs R
Radiat Res
. 2015 Oct;
184(5):482-93.
PMID: 26484401
Many common human cancers, including colon, prostate and breast cancer, express high levels of fatty acid synthase compared to normal human tissues. This elevated expression is associated with protection against...
9.
Rae C, Tesson M, Babich J, Boyd M, Mairs R
EJNMMI Res
. 2013 Nov;
3(1):73.
PMID: 24219987
Background: The radiopharmaceutical 131I-metaiodobenzylguanidine (131I-MIBG) is used for the targeted radiotherapy of noradrenaline transporter (NAT)-expressing neuroblastoma. Enhancement of 131I-MIBG's efficacy is achieved by combination with the topoisomerase I inhibitor topotecan...
10.
Rae C, Tesson M, Babich J, Boyd M, Sorensen A, Mairs R
J Nucl Med
. 2013 Apr;
54(6):953-60.
PMID: 23616582
Unlabelled: Disulfiram has been used for several decades in the treatment of alcoholism. It now shows promise as an anticancer drug and radiosensitizer. Proposed mechanisms of action include the induction...